The effect of statin therapy on plaque regression following acute coronary syndrome

Tang, Xue; Yang, Yuan; Luo, Suxin; Zhao, Yue; Lu, Chin‐Song; Luo, Yongbai; Zhang, Fan

doi:10.1097/mca.0000000000000403

Cited by 18 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The JAPAN-ACS study demonstrated that statin administration significantly inhibits coronary atherosclerosis only following 8 to 12 months of treatment [ 45 ]. A previous meta-analysis also reported that high-intensity statin treatment does not result in plaque regression during the first 3 months in ACS patients; however, plaque regression occurred after 6–12 months and persisted for more than 12 months [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients

Jin

Chen

et al. 2020

Lipids Health Dis

View full text Add to dashboard Cite

Background Whether high-intensity statin treatment provides more clinical benefits compared with standard statin regimens in acute coronary syndrome (ACS) patients remains controversial. This meta-analysis aimed to comparatively assess high-intensity and standard statin regimens for efficacy and safety in patients with ACS. Methods The PubMed, EMBASE, and Cochrane Library databases were searched for studies assessing high-intensity vs. standard statin regimens for ACS treatment from inception to April 2020. The publication language was limited to English, and 16 randomized controlled trials were finally included in this study, with a total of 26,497 patients. Results Compared to the standard statin regimens, the relative ratio (RR) of major adverse cardiovascular events (MACE) in ACS patients treated by high-intensity statin was 0.77 (95%CI, 0.68–0.86; P < 0.00001; prediction interval, 0.56–1.07). In subgroup analysis, high-intensity statin therapy resulted in more clinical benefits regarding MACE compared with standard statin treatment in both Asian (RR = 0.77; 95%CI, 0.61–0.98; P = 0.03) and non-Asian (RR = 0.79; 95%CI, 0.71–0.89; P < 0.0001) patients. Although adverse events were acceptable in patients with ACS administered high-intensity statin therapy, this treatment was associated with a higher rate of adverse events (4.99% vs. 2.98%), including myopathy/myalgia and elevated liver enzymes, as reflected by elevated serum aminotransferase or aminotransferase amounts. Conclusion The current findings indicated that high-intensity statin therapy might be beneficial in patients with ACS, and close monitoring for adverse effects should be performed.

show abstract

Section: Discussionmentioning

confidence: 99%

High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients

Jin

Chen

et al. 2020

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…Наиболее высокую эффективность при этом показывают режимы высокой интенсивно-сти использования этих препаратов. По данным мета-анализа Tang X, et al [40], именно высокие дозы ста-тинов вызывали статистически значимый регресс атеромы (стандартизованная разница средних: -0,27; 95% ДИ: -0,43 до -0,12; р=0,0006) через 6 мес. тера-пии.…”

Section: влияние на маркеры воспаленияunclassified

“…Критерием протеинурии было отношение "белок мочи/креатинин мочи" 500-5000 мг/г. Паци-енты рандомизировались к аторвастатину 80 мг/сут., розувастатину 10 мг/сут., розувастатину 40 По объединенным данным исследований PLANET I и PLANET II аторвастатин, в отличие от розуваста-тина, снизил уровень протеинурии на 18% от исход-ного уровня; р=0,0003, уровень СКФ значимо не снижался: -1,67 мл/мин/1,73 м 2 ; р=0,097. Также был проведен post hoc анализ исследования PLANET I, в ходе которого было оценено влияние терапии ато-рвастатином на уровень СКФ, определяемое на осно-вании уровня цистатина С. Данный анализ также показал безопасность терапии аторвастатином в дозе 80 мг/сут.…”

Section: передовая статья обзор литературыunclassified

Atorvastatin — 20 Years in the Struggle for Life

Gogolashvili¹

2018

Russ J Cardiol

View full text Add to dashboard Cite

“…Statin's role is substantial in CAD treatment and has been well described in numerous studies [12,13]. The major, dose-dependent effect of treatment is low-density lipoprotein (LDL) cholesterol lowering through inhibiting hepatic cholesterol synthesis.…”

Section: Introductionmentioning

confidence: 99%

“…Statins also decrease triglyceride serum level and increase high-density lipoprotein (HDL) cholesterol serum level, but this effect is achievable with higher doses. Intensive treatment may reduce the volume of coronary artery atherosclerotic plaques and change their composition [13,14]. Statin pleiotropic action is based on isoprenoid inhibition and influences numerous signaling pathways.…”

Section: Introductionmentioning

confidence: 99%

Influence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus

Mazurek¹,

Gryga²,

Bugała³

et al. 2019

aoms

View full text Add to dashboard Cite

Introduction: Antiphospholipid antibodies (aPL) affect atherogenesis and may cause thromboembolism in systemic lupus erythematosus (SLE) and coronary artery disease (CAD). Intensive treatment with statins may reduce inflammation and decrease the number of thrombotic events. That may explain the beneficial effect of statin therapy in SLE and CAD. This study was established to investigate the influence of statin treatment on aPL antibody levels and selected endothelial dysfunction markers in CAD and SLE patients. Material and methods: Fifty-eight patients-40 after coronary revascularization (age 38.9 [27-46), 35 males) and 18 with clinically stable SLE (age 38.8 [18-62], 1 male)-were enrolled in the study. In both groups intensive atorvastatin treatment was administered. At baseline and after one year of follow-up serology tests were performed: anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (aβ2GPI), lupus anticoagulant (LA), C-reactive protein (CRP), soluble form of intracellular adhesion molecule-1 (sICAM-1), vWF:Ag. Results: Coronary artery disease patients in one year follow-up revealed a decrease of aβ2GPI IgG and CRP. There was a significant increase in aCL IgG, sICAM-1 and vWF:Ag. In SLE patients aPL levels showed no significant reduction after treatment. Conclusions: In clinically stable patients IgM and IgG class aβ2GPI levels are higher in CAD than in SLE, whereas IgG class aCL levels are lower. Statin treatment decreases the CRP level in both SLE and CAD patients, while decreasing the aβ2GPI IgG level only in CAD patients.

show abstract

The effect of statin therapy on plaque regression following acute coronary syndrome

Abstract: Intensive statin therapy duration over 6 months may be as important as achieved LDL-C of less than or equal to 70 mg/dl in plaque regression following ACS. Intensive statin treatment may lead to an earlier regression compared with low-dose statin therapy.

Cited by 18 publications

References 38 publications

High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients

High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients

Atorvastatin — 20 Years in the Struggle for Life

Influence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus

Contact Info

Product

Resources

About